☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Bayer
Bayer Reports the P-III (OASIS 3) Trial Data of Elinzanetant to Treat Vasomotor Symptoms in Postmenopausal Women
September 11, 2024
Bayer Highlights New Results from the P-I/II Trial of BAY 2927088 for Non-Small Cell Lung Cancer at WCLC 2024
September 10, 2024
Bayer Reports the Initiation of P-III (SOHO-02) Study of BAY 2927088 to Treat Non-Small Cell Lung Cancer (NSCLC)
August 30, 2024
Bayer Partners with NextRNA Therapeutics to Develop Small Molecules Targeting Long Non-Coding RNAs (lncRNAs) for Oncology
August 29, 2024
Bayer Reports the P-III (FINEARTS-HF) Study Data of Finerenone to Prevent Heart Failure with Preserved Ejection Fraction
August 5, 2024
Bayer Submits NDA of Elinzanetant, Seeking Approval in the US for Vasomotor Symptoms Treatment
August 2, 2024
Load more...
Back to Home